NAAG peptidase inhibitor improves motor function and reduces cognitive dysfunction in a model of TBI with secondary hypoxia

Gene G. Gurkoff, Jun Feng Feng, Ken C. Van, Ali Izadi, Rahil Ghiasvand, Kiarash Shahlaie, Minsoo Song, David A. Lowe, Jia Zhou, Bruce G. Lyeth

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Immediately following traumatic brain injury (TBI) and TBI with hypoxia, there is a rapid and pathophysiological increase in extracellular glutamate, subsequent neuronal damage and ultimately diminished motor and cognitive function. N-acetyl-aspartyl glutamate (NAAG), a prevalent neuropeptide in the CNS, is co-released with glutamate, binds to the presynaptic group II metabotropic glutamate receptor subtype 3 (mGluR3) and suppresses glutamate release. However, the catalytic enzyme glutamate carboxypeptidase II (GCP II) rapidly hydrolyzes NAAG into NAA and glutamate. Inhibition of the GCP II enzyme with NAAG peptidase inhibitors reduces the concentration of glutamate both by increasing the duration of NAAG activity on mGluR3 and by reducing degradation into NAA and glutamate resulting in reduced cell death in models of TBI and TBI with hypoxia. In the following study, rats were administered the NAAG peptidase inhibitor PGI-02776 (10 mg/kg) 30 min following TBI combined with a hypoxic second insult. Over the two weeks following injury, PGI-02776-treated rats had significantly improved motor function as measured by increased duration on the rota-rod and a trend toward improved performance on the beam walk. Furthermore, two weeks post-injury, PGI-02776-treated animals had a significant decrease in latency to find the target platform in the Morris water maze as compared to vehicle-treated animals. These findings demonstrate that the application of NAAG peptidase inhibitors can reduce the deleterious motor and cognitive effects of TBI combined with a second hypoxic insult in the weeks following injury.

Original languageEnglish (US)
Pages (from-to)98-107
Number of pages10
JournalBrain Research
Volume1515
DOIs
StatePublished - Jun 17 2013

Fingerprint

Protease Inhibitors
Glutamic Acid
Glutamate Carboxypeptidase II
Wounds and Injuries
Enzymes
Neuropeptides
Cognition
Traumatic Brain Injury
N-acetyl-1-aspartylglutamic acid
Hypoxia
Cognitive Dysfunction
Cell Death
Water
PGI-02776

Keywords

  • Behavior
  • Excitotoxicity N- acetylaspartylglutamate (NAAG)
  • Hypoxia
  • Pre-clinical
  • Traumatic brain injury (TBI)

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Developmental Biology
  • Molecular Biology

Cite this

Gurkoff, G. G., Feng, J. F., Van, K. C., Izadi, A., Ghiasvand, R., Shahlaie, K., ... Lyeth, B. G. (2013). NAAG peptidase inhibitor improves motor function and reduces cognitive dysfunction in a model of TBI with secondary hypoxia. Brain Research, 1515, 98-107. https://doi.org/10.1016/j.brainres.2013.03.043

NAAG peptidase inhibitor improves motor function and reduces cognitive dysfunction in a model of TBI with secondary hypoxia. / Gurkoff, Gene G.; Feng, Jun Feng; Van, Ken C.; Izadi, Ali; Ghiasvand, Rahil; Shahlaie, Kiarash; Song, Minsoo; Lowe, David A.; Zhou, Jia; Lyeth, Bruce G.

In: Brain Research, Vol. 1515, 17.06.2013, p. 98-107.

Research output: Contribution to journalArticle

Gurkoff, GG, Feng, JF, Van, KC, Izadi, A, Ghiasvand, R, Shahlaie, K, Song, M, Lowe, DA, Zhou, J & Lyeth, BG 2013, 'NAAG peptidase inhibitor improves motor function and reduces cognitive dysfunction in a model of TBI with secondary hypoxia', Brain Research, vol. 1515, pp. 98-107. https://doi.org/10.1016/j.brainres.2013.03.043
Gurkoff, Gene G. ; Feng, Jun Feng ; Van, Ken C. ; Izadi, Ali ; Ghiasvand, Rahil ; Shahlaie, Kiarash ; Song, Minsoo ; Lowe, David A. ; Zhou, Jia ; Lyeth, Bruce G. / NAAG peptidase inhibitor improves motor function and reduces cognitive dysfunction in a model of TBI with secondary hypoxia. In: Brain Research. 2013 ; Vol. 1515. pp. 98-107.
@article{a29fe88e382848908586e28c21411c8e,
title = "NAAG peptidase inhibitor improves motor function and reduces cognitive dysfunction in a model of TBI with secondary hypoxia",
abstract = "Immediately following traumatic brain injury (TBI) and TBI with hypoxia, there is a rapid and pathophysiological increase in extracellular glutamate, subsequent neuronal damage and ultimately diminished motor and cognitive function. N-acetyl-aspartyl glutamate (NAAG), a prevalent neuropeptide in the CNS, is co-released with glutamate, binds to the presynaptic group II metabotropic glutamate receptor subtype 3 (mGluR3) and suppresses glutamate release. However, the catalytic enzyme glutamate carboxypeptidase II (GCP II) rapidly hydrolyzes NAAG into NAA and glutamate. Inhibition of the GCP II enzyme with NAAG peptidase inhibitors reduces the concentration of glutamate both by increasing the duration of NAAG activity on mGluR3 and by reducing degradation into NAA and glutamate resulting in reduced cell death in models of TBI and TBI with hypoxia. In the following study, rats were administered the NAAG peptidase inhibitor PGI-02776 (10 mg/kg) 30 min following TBI combined with a hypoxic second insult. Over the two weeks following injury, PGI-02776-treated rats had significantly improved motor function as measured by increased duration on the rota-rod and a trend toward improved performance on the beam walk. Furthermore, two weeks post-injury, PGI-02776-treated animals had a significant decrease in latency to find the target platform in the Morris water maze as compared to vehicle-treated animals. These findings demonstrate that the application of NAAG peptidase inhibitors can reduce the deleterious motor and cognitive effects of TBI combined with a second hypoxic insult in the weeks following injury.",
keywords = "Behavior, Excitotoxicity N- acetylaspartylglutamate (NAAG), Hypoxia, Pre-clinical, Traumatic brain injury (TBI)",
author = "Gurkoff, {Gene G.} and Feng, {Jun Feng} and Van, {Ken C.} and Ali Izadi and Rahil Ghiasvand and Kiarash Shahlaie and Minsoo Song and Lowe, {David A.} and Jia Zhou and Lyeth, {Bruce G.}",
year = "2013",
month = "6",
day = "17",
doi = "10.1016/j.brainres.2013.03.043",
language = "English (US)",
volume = "1515",
pages = "98--107",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",

}

TY - JOUR

T1 - NAAG peptidase inhibitor improves motor function and reduces cognitive dysfunction in a model of TBI with secondary hypoxia

AU - Gurkoff, Gene G.

AU - Feng, Jun Feng

AU - Van, Ken C.

AU - Izadi, Ali

AU - Ghiasvand, Rahil

AU - Shahlaie, Kiarash

AU - Song, Minsoo

AU - Lowe, David A.

AU - Zhou, Jia

AU - Lyeth, Bruce G.

PY - 2013/6/17

Y1 - 2013/6/17

N2 - Immediately following traumatic brain injury (TBI) and TBI with hypoxia, there is a rapid and pathophysiological increase in extracellular glutamate, subsequent neuronal damage and ultimately diminished motor and cognitive function. N-acetyl-aspartyl glutamate (NAAG), a prevalent neuropeptide in the CNS, is co-released with glutamate, binds to the presynaptic group II metabotropic glutamate receptor subtype 3 (mGluR3) and suppresses glutamate release. However, the catalytic enzyme glutamate carboxypeptidase II (GCP II) rapidly hydrolyzes NAAG into NAA and glutamate. Inhibition of the GCP II enzyme with NAAG peptidase inhibitors reduces the concentration of glutamate both by increasing the duration of NAAG activity on mGluR3 and by reducing degradation into NAA and glutamate resulting in reduced cell death in models of TBI and TBI with hypoxia. In the following study, rats were administered the NAAG peptidase inhibitor PGI-02776 (10 mg/kg) 30 min following TBI combined with a hypoxic second insult. Over the two weeks following injury, PGI-02776-treated rats had significantly improved motor function as measured by increased duration on the rota-rod and a trend toward improved performance on the beam walk. Furthermore, two weeks post-injury, PGI-02776-treated animals had a significant decrease in latency to find the target platform in the Morris water maze as compared to vehicle-treated animals. These findings demonstrate that the application of NAAG peptidase inhibitors can reduce the deleterious motor and cognitive effects of TBI combined with a second hypoxic insult in the weeks following injury.

AB - Immediately following traumatic brain injury (TBI) and TBI with hypoxia, there is a rapid and pathophysiological increase in extracellular glutamate, subsequent neuronal damage and ultimately diminished motor and cognitive function. N-acetyl-aspartyl glutamate (NAAG), a prevalent neuropeptide in the CNS, is co-released with glutamate, binds to the presynaptic group II metabotropic glutamate receptor subtype 3 (mGluR3) and suppresses glutamate release. However, the catalytic enzyme glutamate carboxypeptidase II (GCP II) rapidly hydrolyzes NAAG into NAA and glutamate. Inhibition of the GCP II enzyme with NAAG peptidase inhibitors reduces the concentration of glutamate both by increasing the duration of NAAG activity on mGluR3 and by reducing degradation into NAA and glutamate resulting in reduced cell death in models of TBI and TBI with hypoxia. In the following study, rats were administered the NAAG peptidase inhibitor PGI-02776 (10 mg/kg) 30 min following TBI combined with a hypoxic second insult. Over the two weeks following injury, PGI-02776-treated rats had significantly improved motor function as measured by increased duration on the rota-rod and a trend toward improved performance on the beam walk. Furthermore, two weeks post-injury, PGI-02776-treated animals had a significant decrease in latency to find the target platform in the Morris water maze as compared to vehicle-treated animals. These findings demonstrate that the application of NAAG peptidase inhibitors can reduce the deleterious motor and cognitive effects of TBI combined with a second hypoxic insult in the weeks following injury.

KW - Behavior

KW - Excitotoxicity N- acetylaspartylglutamate (NAAG)

KW - Hypoxia

KW - Pre-clinical

KW - Traumatic brain injury (TBI)

UR - http://www.scopus.com/inward/record.url?scp=84878499000&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878499000&partnerID=8YFLogxK

U2 - 10.1016/j.brainres.2013.03.043

DO - 10.1016/j.brainres.2013.03.043

M3 - Article

C2 - 23562458

AN - SCOPUS:84878499000

VL - 1515

SP - 98

EP - 107

JO - Brain Research

JF - Brain Research

SN - 0006-8993

ER -